CN105734136B - 一种检测人braf基因突变的探针法及检测试剂盒 - Google Patents
一种检测人braf基因突变的探针法及检测试剂盒 Download PDFInfo
- Publication number
- CN105734136B CN105734136B CN201610178463.6A CN201610178463A CN105734136B CN 105734136 B CN105734136 B CN 105734136B CN 201610178463 A CN201610178463 A CN 201610178463A CN 105734136 B CN105734136 B CN 105734136B
- Authority
- CN
- China
- Prior art keywords
- braf
- concentration
- pcr
- sequence
- internal reference
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 41
- 101150048834 braF gene Proteins 0.000 title claims abstract description 38
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 26
- 102200055464 rs113488022 Human genes 0.000 claims abstract description 152
- 239000000523 sample Substances 0.000 claims abstract description 67
- 239000007788 liquid Substances 0.000 claims abstract description 64
- 230000035772 mutation Effects 0.000 claims abstract description 42
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 30
- 239000011541 reaction mixture Substances 0.000 claims abstract description 26
- 238000003753 real-time PCR Methods 0.000 claims abstract description 21
- 230000003321 amplification Effects 0.000 claims description 28
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 28
- 239000013612 plasmid Substances 0.000 claims description 17
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 15
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 15
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 12
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 claims description 11
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 claims description 11
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 claims description 11
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 229930024421 Adenine Natural products 0.000 claims description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 6
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 6
- 229960000643 adenine Drugs 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 6
- 229940104230 thymidine Drugs 0.000 claims description 6
- 239000007984 Tris EDTA buffer Substances 0.000 claims description 5
- 230000004087 circulation Effects 0.000 claims description 4
- 238000010791 quenching Methods 0.000 claims description 4
- 230000000171 quenching effect Effects 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 3
- 125000006853 reporter group Chemical group 0.000 claims description 3
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 238000012408 PCR amplification Methods 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 101150040459 RAS gene Proteins 0.000 description 2
- 241000218636 Thuja Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- 108091092742 A-DNA Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000042888 RAF family Human genes 0.000 description 1
- 108091082327 RAF family Proteins 0.000 description 1
- 101150076031 RAS1 gene Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101150062264 Raf gene Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- -1 cytimidine Chemical compound 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002243 furanoses Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
BRAF V600E上游引物 | 3μM |
BRAF V600E下游引物 | 3μM |
BRAF V600E探针 | 3μM |
内参上游引物 | 2μM |
内参下游引物 | 2μM |
内参探针 | 2μM |
dUTP | 0.2μM |
尿嘧啶DNA糖基化酶(UNG) | 0.01U/μl |
Claims (29)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610178463.6A CN105734136B (zh) | 2016-03-25 | 2016-03-25 | 一种检测人braf基因突变的探针法及检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610178463.6A CN105734136B (zh) | 2016-03-25 | 2016-03-25 | 一种检测人braf基因突变的探针法及检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105734136A CN105734136A (zh) | 2016-07-06 |
CN105734136B true CN105734136B (zh) | 2019-07-30 |
Family
ID=56251546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610178463.6A Active CN105734136B (zh) | 2016-03-25 | 2016-03-25 | 一种检测人braf基因突变的探针法及检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105734136B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106434918A (zh) * | 2016-09-26 | 2017-02-22 | 复旦大学附属华山医院 | 特定基因突变在检测垂体腺瘤的分子诊断和靶向治疗中的应用 |
CN108374009A (zh) * | 2018-05-07 | 2018-08-07 | 求臻医学科技(北京)有限公司 | 用于检测braf突变的引物对和探针的组合产品、组合物、试剂盒及其应用 |
CN110938693B (zh) * | 2019-12-04 | 2022-02-25 | 阅尔基因技术(苏州)有限公司 | 用于检测braf基因突变的引物组、试剂盒及方法 |
CN112029836A (zh) * | 2020-10-13 | 2020-12-04 | 苏州中科先进技术研究院有限公司 | 检测braf基因突变的核酸组合物及试剂盒和braf基因突变的检测方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104774962A (zh) * | 2015-04-29 | 2015-07-15 | 苏州工业园区为真生物医药科技有限公司 | 检测braf基因突变的试剂盒及其检测方法 |
CN105039514A (zh) * | 2015-06-02 | 2015-11-11 | 武汉友芝友医疗科技有限公司 | 人类braf基因v600e突变检测试剂盒 |
-
2016
- 2016-03-25 CN CN201610178463.6A patent/CN105734136B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104774962A (zh) * | 2015-04-29 | 2015-07-15 | 苏州工业园区为真生物医药科技有限公司 | 检测braf基因突变的试剂盒及其检测方法 |
CN105039514A (zh) * | 2015-06-02 | 2015-11-11 | 武汉友芝友医疗科技有限公司 | 人类braf基因v600e突变检测试剂盒 |
Non-Patent Citations (2)
Title |
---|
Allele Specific Locked Nucleic Acid Quantitative PCR (ASLNAqPCR): An Accurate and Cost-Effective Assay to Diagnose and Quantify KRAS and BRAF Mutation;Luca Morandi等;《Plos one》;20120430;第1-13页 |
BRAF基因V600E 突变检测的荧光PCR方法的建立;曲守方等;《药物分析杂志》;20151231;第35卷(第8期);第1358-1362页 |
Also Published As
Publication number | Publication date |
---|---|
CN105734136A (zh) | 2016-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101969971B1 (ko) | 양기능성 pna 프로브를 이용한 융해곡선 분석방법, 및 이를 이용한 현미부수체 불안정성의 진단방법 및 현미부수체 불안정성 진단용 키트 | |
CN105734136B (zh) | 一种检测人braf基因突变的探针法及检测试剂盒 | |
CN105331699A (zh) | 检测人tert基因启动子突变的探针法及其试剂盒 | |
JP2022530483A (ja) | ヌクレアーゼ協同pcr原理に基づいて低存在比のdna突然変異を濃縮する検出技術システムおよび使用 | |
CN106755456B (zh) | 用于线粒体全基因组检测的引物组合及试剂盒 | |
TWI781518B (zh) | 用以診斷脊髓性肌肉萎縮症之套組及其用途 | |
CN114085903B (zh) | 检测线粒体3243a>g突变的引物对探针组合产品及其试剂盒与检测方法 | |
JP2022130509A (ja) | 分析方法及びキット | |
CN111088329A (zh) | 荧光复合扩增体系、试剂盒及其应用 | |
CN104928355A (zh) | 检测braf基因突变的方法及其试剂盒 | |
US10851408B2 (en) | Methods and kits for detecting gene mutations | |
CN107513577A (zh) | 一种高效检测egfrt790m突变体的方法以及用于检测的探针和试剂盒 | |
CN110846408A (zh) | 用于检测ttn基因突变的引物组合及其应用 | |
US20230304081A1 (en) | Primer and probe design method, detection composition, and kit for mirna detection | |
KR101775953B1 (ko) | 돌연변이 유전자 검사 방법 및 킷트 | |
CN108913774A (zh) | 一种c-KIT体细胞突变基因检测试剂盒及其检测方法 | |
CN114891928A (zh) | 一种麻疹病毒、风疹病毒和腮腺炎病毒核酸检测的引物探针组合物和检测试剂盒 | |
CN109355362B (zh) | 一种高灵敏的SNPs检测体系及应用 | |
EP3907298A1 (en) | Single nucleic acid for real-time detection of genetic variation of single target gene, and detection method using same | |
EP3421611B1 (en) | Acute myelogenous leukemia diagnostic method targeting prohibitin gene | |
CN116479116A (zh) | 可排除smn2干扰的smn1基因检测的试剂盒及检测方法 | |
CN105734137A (zh) | 一种检测人h3f3a基因突变的探针法及检测试剂盒 | |
CN116426617B (zh) | 一种基于发卡结构和酶切机制的高灵敏突变检测体系和应用 | |
CN112980932B (zh) | 一种检测基因突变的核苷酸及其组合物和方法 | |
CN115820862A (zh) | 一种检测人egfr基因多突变位点的数字pcr试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190416 Address after: 200439 No.111 Gaoyi Road, Baoshan District, Shanghai Applicant after: SHANGHAI JINCHUANG MEDICAL INSPECTION INSTITUTE Co.,Ltd. Applicant after: HANGZHOU FANSHENGZI MEDICAL LABORATORY Co.,Ltd. Address before: 200439 No.111 Gaoyi Road, Baoshan District, Shanghai Applicant before: SHANGHAI JINCHUANG MEDICAL INSPECTION INSTITUTE Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190628 Address after: 102206 Room 201, 2nd Floor, 11 Building, No. 1 District, No. 8 Life Garden Road, Zhongguancun Life Science Park, Huilongguan Town, Changping District, Beijing Applicant after: GENETRON HEALTH (BEIJING) Co.,Ltd. Applicant after: SHANGHAI JINCHUANG MEDICAL INSPECTION INSTITUTE Co.,Ltd. Applicant after: HANGZHOU FANSHENGZI MEDICAL LABORATORY Co.,Ltd. Address before: 200439 No.111 Gaoyi Road, Baoshan District, Shanghai Applicant before: SHANGHAI JINCHUANG MEDICAL INSPECTION INSTITUTE Co.,Ltd. Applicant before: HANGZHOU FANSHENGZI MEDICAL LABORATORY Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191111 Address after: 400084 8-1, 8-2, building 5, No. 101, Cuibai Road, Chunhui road street, Dadukou District, Chongqing Co-patentee after: GENETRON HEALTH (BEIJING) Co.,Ltd. Patentee after: GENETRON HEALTH (CHONGQING) CO.,LTD. Co-patentee after: SHANGHAI JINCHUANG MEDICAL INSPECTION INSTITUTE Co.,Ltd. Co-patentee after: HANGZHOU FANSHENGZI MEDICAL LABORATORY Co.,Ltd. Address before: 102206 Beijing City, Changping District small town life Zhongguancun Life Science Park Road No. 8 School District No. 11 Building 2 Room 201 Co-patentee before: SHANGHAI JINCHUANG MEDICAL INSPECTION INSTITUTE Co.,Ltd. Patentee before: GENETRON HEALTH (BEIJING) Co.,Ltd. Co-patentee before: HANGZHOU FANSHENGZI MEDICAL LABORATORY Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A probe method and kit for detecting BRAF gene mutation Effective date of registration: 20200902 Granted publication date: 20190730 Pledgee: Zhongguancun Beijing technology financing Company limited by guarantee Pledgor: GENETRON HEALTH (CHONGQING) Co.,Ltd.|GENETRON HEALTH (BEIJING) Co.,Ltd.|HANGZHOU FANSHENGZI MEDICAL LABORATORY Co.,Ltd.|SHANGHAI JINCHUANG MEDICAL INSPECTION INSTITUTE Co.,Ltd. Registration number: Y2020990001061 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: 400084 8-1, 8-2, building 5, 101 Cuibai Road, Chunhui road street, Dadukou District, Chongqing Patentee after: GENETRON HEALTH (CHONGQING) Co.,Ltd. Patentee after: GENETRON HEALTH (BEIJING) Co.,Ltd. Patentee after: SHANGHAI JINCHUANG MEDICAL INSPECTION INSTITUTE Co.,Ltd. Patentee after: Hangzhou Jichen junchuang medical laboratory Co.,Ltd. Address before: 400084 8-1, 8-2, building 5, 101 Cuibai Road, Chunhui road street, Dadukou District, Chongqing Patentee before: GENETRON HEALTH (CHONGQING) Co.,Ltd. Patentee before: GENETRON HEALTH (BEIJING) Co.,Ltd. Patentee before: SHANGHAI JINCHUANG MEDICAL INSPECTION INSTITUTE Co.,Ltd. Patentee before: HANGZHOU FANSHENGZI MEDICAL LABORATORY Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211126 Granted publication date: 20190730 Pledgee: Zhongguancun Beijing technology financing Company limited by guarantee Pledgor: GENETRON HEALTH (CHONGQING) CO.,LTD.|GENETRON HEALTH (BEIJING) Co.,Ltd.|HANGZHOU FANSHENGZI MEDICAL LABORATORY Co.,Ltd.|SHANGHAI JINCHUANG MEDICAL INSPECTION INSTITUTE Co.,Ltd. Registration number: Y2020990001061 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230105 Address after: 400084 8-1, 8-2, building 5, 101 Cuibai Road, Chunhui road street, Dadukou District, Chongqing Patentee after: GENETRON HEALTH (CHONGQING) CO.,LTD. Patentee after: GENETRON HEALTH (BEIJING) Co.,Ltd. Patentee after: GENETRON HEALTH(BEIJING) LABORATORY Co.,Ltd. Patentee after: Hangzhou Jichen junchuang medical laboratory Co.,Ltd. Address before: 400084 8-1, 8-2, building 5, 101 Cuibai Road, Chunhui road street, Dadukou District, Chongqing Patentee before: GENETRON HEALTH (CHONGQING) CO.,LTD. Patentee before: GENETRON HEALTH (BEIJING) Co.,Ltd. Patentee before: SHANGHAI JINCHUANG MEDICAL INSPECTION INSTITUTE Co.,Ltd. Patentee before: Hangzhou Jichen junchuang medical laboratory Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230908 Address after: 8-1, 8-2, Building 5, No. 101 Cuibai Road, Chunhui Road Street, Dadukou District, Chongqing, 400000 Patentee after: GENETRON HEALTH (CHONGQING) CO.,LTD. Patentee after: GENETRON HEALTH (BEIJING) Co.,Ltd. Patentee after: GENETRON HEALTH(BEIJING) LABORATORY Co.,Ltd. Address before: 400084 8-1, 8-2, building 5, 101 Cuibai Road, Chunhui road street, Dadukou District, Chongqing Patentee before: GENETRON HEALTH (CHONGQING) CO.,LTD. Patentee before: GENETRON HEALTH (BEIJING) Co.,Ltd. Patentee before: GENETRON HEALTH(BEIJING) LABORATORY Co.,Ltd. Patentee before: Hangzhou Jichen junchuang medical laboratory Co.,Ltd. |
|
TR01 | Transfer of patent right |